The present study describes the optimization of (68)Ga radiolabeling with PAMAM dendrimer-DOTA conjugate. A conjugate (PAMAM-DOTA) concentration of 11.69µM, provided best radiolabeling efficiency of more than 93.0% at pH 4.0, incubation time of 30.0min and reaction temperature ranging between 90 and 100°C. The decay corrected radiochemical yield was found to be 79.4±0.01%. The radiolabeled preparation ([(68)Ga]-DOTA-PAMAM-D) remained stable (radiolabeling efficiency of 96.0%) at room temperature and in serum for up to 4-h. The plasma protein binding was observed to be 21.0%. After intravenous administration, 50.0% of the tracer cleared from the blood circulation by 30-min and less than 1.0% of the injected activity remained in blood by 1.0h. The animal biodistribution studies demonstrated that the tracer excretes through the kidneys and about 0.33% of the %ID/g accumulated in the tumor at 1h post injection. The animal organ's biodistribution data was supported by animal PET imaging showing good 'non-specific' tracer uptake in tumor and excretion is primarily through kidneys. Additionally, DOTA-PAMAM-D conjugation with αVβ3 receptors targeting peptides and drug loading on the dendrimers may improve the specificity of the (68)Ga labeled product for imaging and treating angiogenesis respectively.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538890PMC
http://dx.doi.org/10.1016/j.apradiso.2015.07.021DOI Listing

Publication Analysis

Top Keywords

68ga labeled
8
animal biodistribution
8
pet imaging
8
radiolabeling efficiency
8
radiolabeling
4
radiolabeling optimization
4
optimization characterization
4
characterization 68ga
4
labeled dota-polyamido-amine
4
dota-polyamido-amine dendrimer
4

Similar Publications

Background: The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.

Materials And Methods: We found over 3500 articles discussing the role of PET-CT in Pca patients' management published within 1990-2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered.

View Article and Find Full Text PDF

B-CLL with negative F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastases.

EJNMMI Rep

January 2025

Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine & Endocrinology, University Hospital, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.

Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-radioligands is currently suggested by several clinical guidelines for the assessment of prostate cancer (PCa) in various clinical settings. However, PSMA will also be overexpressed in different cancers, which should be considered on the PSMA PET/CT reading in patients with concomitant neoplastic diseases. We report a case of 82-year-old male presented with prostate and history of oesophageal cancer and B-cell chronic lymphocytic leukemia (B-CLL).

View Article and Find Full Text PDF

Melanoma, with its steadily rising global incidence, is characterized by high invasiveness, leading to poor prognosis in advanced stages. There remains an unmet clinical need for the development of radiolabeled PET imaging probes for the early diagnosis of melanoma. Integrin VLA-4, a key factor in melanoma metastasis, presents a promising protein target to address the specificity shortcomings of existing probes in melanoma imaging.

View Article and Find Full Text PDF

Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease.

Bioconjug Chem

January 2025

Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China.

To enhance the affinity of peptide ligands for their targets, covalent warheads can be engineered to facilitate irreversible binding. This study aimed at exploring the potential of a Ga-labeled peptidomimetic radioligand, [Ga]Ga-DOTA-RQAR-kbt, for PET imaging through its irreversible binding to the suppression of tumorigenicity 14 (ST14). An Arg-Gln-Ala-Arg (RQAR) tetrapeptide was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid for gallium-68 radiolabeling.

View Article and Find Full Text PDF

Fibroblast activation protein inhibitors (FAPIs) labeled with gallium-68 and lutetium-177 show potential for use in the diagnosis and treatment of various cancers expressing FAP. However, Lu-labeled FAPIs often exhibit short tumor retention time, limiting their therapeutic applications. To improve tumor retention, we synthesized three radiolabeled dimeric FAPIs, [F], [Cu], and [Ga].

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!